uniQure N.V. (QURE) financial statements (2021 and earlier)

Company profile

Business Address PAASHEUVELWEG 25A
AMSTERDAM, 1105 BP
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments378235159132
Cash and cash equivalents378235159132
Receivables1029
Prepaid expense5111
Other current assets1011
Total current assets:384237163144
Noncurrent Assets
Operating lease, right-of-use asset27
Property, plant and equipment29293436
Intangible assets, net (including goodwill)66109
Goodwill0110
Intangible assets, net (excluding goodwill)55108
Other noncurrent assets  22
Other undisclosed noncurrent assets32  
Total noncurrent assets:64374746
TOTAL ASSETS:449274210190
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities189910
Accounts payable6436
Accrued liabilities12   
Employee-related liabilities 664
Deferred revenue8
Debt6 11
Deferred rent credit 0
Business combination, contingent consideration, liability  1 
Deferred revenue and credits57
Contract with customer, liability8
Other liabilities 110
Other undisclosed current liabilities 225
Total current liabilities:32201923
Noncurrent Liabilities
Long-term debt and lease obligation67352020
Long-term debt, excluding current maturities36352020
Operating lease, liability31
Liabilities, other than long-term debt27398184
Deferred revenue and credits7782
Deferred revenue23
Contract with customer, liability29
Deferred rent credit 9
Other liabilities1010
Business combination, contingent consideration, liability  32
Derivative instruments and hedges, liabilities311 
Total noncurrent liabilities:9474101104
Total liabilities:12694120127
Stockholders' equity
Stockholders' equity attributable to parent3231808964
Common stock3222
Additional paid in capital987720567465
Accumulated other comprehensive loss(7)(7)(4)(7)
Accumulated deficit(660)(536)(475)(396)
Total stockholders' equity:3231808964
TOTAL LIABILITIES AND EQUITY:449274210190

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues7111325
Revenue, net41
Other income2   
Cost of revenue(95)(1)(1)(1)
Cost of goods and services sold(2)(1)(1)(1)
Gross profit:(87)101224
Operating expenses(34)(100)(97)(99)
Other operating expense, net
(Other Expenses)
(2)   
Other undisclosed operating income22133
Operating loss:(121)(88)(71)(72)
Nonoperating income (expense)17(6)2
Investment income, nonoperating4300
Foreign currency transaction gain (loss), before tax(0)4(4)1
Other nonoperating income (expense)(3)0(2)1
Interest and debt expense(4)(2)(2)(2)
Loss from continuing operations before income taxes:(124)(83)(79)(72)
Income tax expense (benefit) (0)0(1)
Net loss available to common stockholders, diluted:(124)(83)(79)(73)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(124)(83)(79)(73)
Comprehensive loss:(124)(83)(79)(73)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1(5)30
Comprehensive loss, net of tax, attributable to parent:(124)(89)(77)(73)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: